Hikari Tsushin Inc. Acquires Shares of 6,107 Becton, Dickinson and Company $BDX

Hikari Tsushin Inc. bought a new stake in Becton, Dickinson and Company (NYSE:BDX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,107 shares of the medical instruments supplier’s stock, valued at approximately $1,185,000.

Several other institutional investors have also recently made changes to their positions in BDX. Crux Wealth Advisors lifted its position in shares of Becton, Dickinson and Company by 0.8% during the 4th quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock worth $1,222,000 after buying an additional 49 shares during the last quarter. Larson Financial Group LLC grew its position in shares of Becton, Dickinson and Company by 1.7% in the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $627,000 after buying an additional 53 shares during the last quarter. Camelot Portfolios LLC raised its stake in Becton, Dickinson and Company by 1.5% during the 4th quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock worth $688,000 after acquiring an additional 54 shares in the last quarter. McElhenny Sheffield Capital Management LLC lifted its position in Becton, Dickinson and Company by 3.6% in the fourth quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock valued at $309,000 after acquiring an additional 55 shares during the last quarter. Finally, Atlantic Union Bankshares Corp lifted its position in Becton, Dickinson and Company by 0.9% in the fourth quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock valued at $1,185,000 after acquiring an additional 57 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

BDX has been the topic of several research reports. The Goldman Sachs Group dropped their price objective on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Stifel Nicolaus decreased their target price on Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. Piper Sandler dropped their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Weiss Ratings lowered Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Finally, Barclays boosted their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $183.64.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $151.48, for a total transaction of $166,628.00. Following the completion of the transaction, the executive vice president owned 14,272 shares in the company, valued at approximately $2,161,922.56. This represents a 7.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at $16,122,355.05. This trade represents a 2.45% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,013 shares of company stock worth $593,434 over the last three months. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $147.40 on Friday. The stock’s 50-day moving average price is $150.21 and its 200 day moving average price is $174.25. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $40.62 billion, a PE ratio of 37.32, a price-to-earnings-growth ratio of 10.46 and a beta of 0.22. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company’s revenue was up 5.2% on a year-over-year basis. During the same period last year, the business posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.